Pharmacological data suggest that the actions of -antimiine drugs such as sumatriptn may be medated by 5-HT1D-lke serotonin recepors on trigemnhovascular nerve endings. We sought molecular evidence for the expreion of an mRNA species encoding the 5-HT1D receptor subtype in guinea pig and human trigeminal g i, using the polymerase chain reaction with oigon tides uniquely homologous to the coding sequences of the 5-HT1B/D family (human 5-HTmDa and 5-HT1DP; rat 5-HTo The 5-HT1D serotonin receptor subtype comprises a family of at least two closely related receptors encoded by distinct genes (1, 2) designated 5-HTDDa and 5-HT1DP (2) or 5-HT1D and 5-HT1I (3). Pharmacological evidence supports the existence of prejunctional serotonin (5-hydroxytryptamine, 5-HT) receptors resembling 5-HTj and 5-HT1B on trigeminovascular axons transmitting nociceptive information from guinea pig and rat meninges, respectively (4, 5) . Serotonin agonists and antimigraine compounds such as sumatriptan and ergot alkaloids bind to these receptor sites to block the development of meningeal neurogenic inflammation and to suppress nociceptive activity within trigeminovascular afferents (6-10).
The 5-HT1D serotonin receptor subtype comprises a family of at least two closely related receptors encoded by distinct genes (1, 2) designated 5-HTDDa and 5-HT1DP (2) or 5-HT1D and 5-HT1I (3) . Pharmacological evidence supports the existence of prejunctional serotonin (5-hydroxytryptamine, 5-HT) receptors resembling 5-HTj and 5-HT1B on trigeminovascular axons transmitting nociceptive information from guinea pig and rat meninges, respectively (4, 5) . Serotonin agonists and antimigraine compounds such as sumatriptan and ergot alkaloids bind to these receptor sites to block the development of meningeal neurogenic inflammation and to suppress nociceptive activity within trigeminovascular afferents (6) (7) (8) (9) (10) .
Receptors for the 5-HTlD-like subtype have also been pharmacologically characterized on postjunctional vascular smooth muscle, where they mediate vasoconstriction (11) . Recently, Northern blot analyses provided evidence for the selective expression of the 5-HT1Dq receptor gene in pial blood vessels (12) . Activation of contractile postjunctional receptors on human coronary and cerebral arteries has been linked to the development of coronary vasospasm (13, 14) , myocardial infarction (15) , and possibly stroke, complicating the treatment of migraine.
Our own studies were undertaken to examine the possible expression of a selective receptor subtype which differentiates the pre-and postjunctional 5-HT1D receptor family. We used polymerase chain reaction (PCR)-based amplification to show expression of mRNA species homologous to members ofthe 5 IThe sequences reported in this paper have been deposited in the GenBank data base (accession nos. U07022).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. genes were also made (W144, 100%o sequence identity to 5-HTlDa and 90% identity to 5-HT1DS; W145, 100%o identity to 5-HTlD, and 45% identity to 5-HT1DP; W146, 100%o identity to 5-HT1D9 and 45% identity to 5-HT1Da) ( Fig. 1 ). 5-HTIDaspecific primers amplify 149 bp, whereas 5-HTlDP-specific primers amplify 158 bp (see Fig. 4 ). PCR products were separated by gel electrophoresis using a 2% or 3% agarose gel in 90 mM Tris/90 mM boric acid/2 mM EDTA containing ethidium bromide (1 ug/ml; Fisher Scientific). Upon completion, the gel was viewed under a UV light and photographed.
The DNA amplified from guinea pig cDNA using the W72 and W73 primers was sequenced with thefmol PCR sequencing protocol (Promega). The W72 and W73 primers were end-labeled with [y-32P]ATP (New England Nuclear) and extended in the presence ofdideoxynucleotides. The reaction products were separated in a 6% acrylamide/urea gel, which was then dried and exposed to film.
RESULTS
Approximately 1 pg of total RNA per mg of wet weight was extracted from each of the guinea pig tissues and used to generate cDNA pools. Primers directed to conserved regions of the 5-HT1Da gene were used for PCR amplification (Fig. 1) . Amplified DNA ofthe predicted size (-350 bp) was produced from samples of trigeminal ganglia and cerebella in each of three separate experiments (Fig. 2) . PCR products did not appear if the reverse transcriptase step was omitted. Evidence for expression ofa 5-HTID receptor gene was not found in the guinea pig striatum, hippocampus, and neocortex (Fig.   2) , although previous studies had demonstrated 5-HT1D receptor expression in human tissues (2, 3) .
The amplified DNA from the guinea pig trigeminal ganglion cDNA was sequenced by a PCR cycle sequencing protocol. A single DNA sequence was found, which was homologous to the appropriate region ofthe human 5-HTD receptor genes (Fig. 3) . The guinea pig nucleotide sequence was 85% and 71% identical to the human 5-HTlDa and 5-HT1D receptor sequences, respectively; the deduced 116-amino acid sequence was 92% and 74% identical, respectively.
These data suggested that the message for the 5-HT1Da receptor was expressed in guinea pig trigeminal ganglia. However, without the known sequences of the receptor subtypes in guinea pig, it was not possible to definitively determine whether mRNA species of both 5-HTlDa and 5-HT1D subtypes were present. To better address the question of expression of 5-HTlD receptor subtypes, we took a similar PCR-based approach using trigeminal ganglia from humans. Ganglia from two postmortem cases showed convincing evidence of 5-HTlDa receptor mRNA. Ganglia from six other cases were negative, possibly due to degradation of the mRNA after death, although there was no obvious relationship between postmortem time and receptor message detection.
Primers specific for 5-HTlDa and 5-HT1Dp receptor subtypes were designed ( Fig. 1) samples. Amplified DNA of the expected size was detected in both specimens when PCR was performed with 5-HT1Da-specific primers, but not with 5-HTlD-specific primers (Fig.  4, lanes A and B) . Both sets ofprimers successfully amplified DNA of expected sizes from genomic DNA (lanes C and D) and did not amplify DNA from RNA samples not treated with reverse transcriptase (lanes E and F). As a further positive control, human striatal tissue, which is positive for both 5-HT1Da and 5-HT1Dp receptor messages (2, 3) , was used in the PCR. DNA was successfully amplified from striatum cDNA using both 5-HTlDa and 5-HT1D9 receptor-specific primers (Fig. 5) . (1), suggesting that its actions may well be mediated by one or both receptor subtypes, depending upon the extent to which the two genes are expressed. However, the importance of other 5-HT receptor subtypes which bind sumatriptan cannot be excluded. For example, recently an intronless gene encoding a 5-HT1F (5-HT1E) receptor subtype to which sumatriptan binds with high affinity was isolated from a human genomic library (19) (20) (21) . Sumatriptan also binds to 5-HT1A and 5-HT1B receptors, albeit with somewhat lower affinities (22, 23) .
The pharmacological properties of the trigeminovascular 5-HT receptor resembles most closely the 5-HT1D (guinea pig) and 5-HT1B (rat) receptors among the defined subtypes (4, 24) , with notable exceptions (5, 24). 5-HT1B and 5-HT1D receptor subtypes are often located prejunctionally or presynaptically and are negatively coupled to neurotransmitter release (25) (26) (27) (28) . Within the rat (and presumably the human) trigeminovascular system, prejunctional receptors to which sumatriptan binds inhibit neuropeptide release (24) , thereby blocking the development of neurogenic inflamma- tion. Consistent with this formulation, expression of a gene encoding the 5-HT1B receptor was found in rat trigeminal ganglion cells by in situ hybridization (29) . The rat 5-HT1B receptor gene exhibits remarkable sequence homology to the human 5-HT1Dp receptor gene. Hence, the lack of 5-HT1D8 receptor message in human trigeminal ganglia was unexpected because of evolutionary considerations and because of results suggesting the existence of prejunctional 5-HT1B trigeminovascular receptors in the rat that mediate the effects of sumatriptan (4) . However, the expression of different receptor isotypes mediating identical responses in cells from different species has been observed previously (30, 31) and establishes precedent for the unanticipated results obtained in human trigeminal ganglia. The mechanisms of action of sumatriptan in rat may be clarified by studies of a newly described 5-HTlD-like receptor (32, 33) which, on the basis of sequence homology, tissue distribution, and pharmacology, is likely to be the species homolog of the human 5-HT1Da receptor.
In summary, our present findings illustrate that the 5-HT prejunctional receptor mRNA expressed by human trigeminovascular neurons is likely to be the 5-HT1Da and not the 5-HT1D9 receptor subtype. Our results also suggest that the receptor subtype mediating constriction of cerebral and coronary arteries (11) (12) (13) (14) (15) is distinct from the 5-HT receptor subtype mediating blockade of neural transmission. Consequently, it may be possible to design therapeutically useful, subtype-specific drugs which do not constrict coronary or pial vessels (11, 34, 35) . At the same time, these new drugs would establish the relative importance of neurogenic versus vascular mechanisms in migraine.
